Lantheus (NASDAQ:LNTH) Releases FY24 Earnings Guidance

Lantheus (NASDAQ:LNTH - Get Free Report) issued an update on its FY24 earnings guidance on Wednesday morning. The company provided earnings per share guidance of $6.65-6.70 for the period, compared to the consensus earnings per share estimate of $6.66. The company issued revenue guidance of $1.51-1.52 billion, compared to the consensus revenue estimate of $1.52 billion. Lantheus also updated its FY 2024 guidance to 6.650-6.700 EPS.

Lantheus Stock Down 20.7 %

Shares of Lantheus stock traded down $23.79 during trading on Wednesday, reaching $91.17. The company's stock had a trading volume of 5,732,994 shares, compared to its average volume of 981,468. The company has a quick ratio of 4.41, a current ratio of 4.68 and a debt-to-equity ratio of 0.55. The company has a market cap of $6.33 billion, a price-to-earnings ratio of 15.36 and a beta of 0.51. Lantheus has a 1-year low of $50.20 and a 1-year high of $126.89. The company has a 50-day simple moving average of $108.41 and a two-hundred day simple moving average of $95.60.

Wall Street Analyst Weigh In

LNTH has been the subject of a number of recent analyst reports. B. Riley raised their price objective on Lantheus from $105.00 to $146.00 and gave the stock a "buy" rating in a research report on Thursday, July 25th. Redburn Atlantic initiated coverage on Lantheus in a research note on Tuesday, September 3rd. They issued a "buy" rating and a $175.00 target price for the company. JMP Securities reduced their target price on Lantheus from $130.00 to $125.00 and set a "market outperform" rating for the company in a research note on Thursday, August 1st. Leerink Partners raised their target price on Lantheus from $106.00 to $127.00 and gave the stock an "outperform" rating in a research note on Thursday, July 11th. Finally, Truist Financial reduced their target price on Lantheus from $141.00 to $135.00 and set a "buy" rating for the company in a research note on Thursday, August 1st. Two equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat.com, Lantheus currently has an average rating of "Moderate Buy" and a consensus price target of $126.00.

Insider Buying and Selling at Lantheus

In other Lantheus news, President Paul Blanchfield sold 2,000 shares of Lantheus stock in a transaction dated Thursday, August 8th. The stock was sold at an average price of $96.39, for a total transaction of $192,780.00. Following the completion of the transaction, the president now owns 98,980 shares in the company, valued at approximately $9,540,682.20. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In other news, Director Gerard Ber sold 15,500 shares of the firm's stock in a transaction dated Monday, August 12th. The stock was sold at an average price of $96.48, for a total transaction of $1,495,440.00. Following the sale, the director now directly owns 21,221 shares in the company, valued at $2,047,402.08. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, President Paul Blanchfield sold 2,000 shares of the firm's stock in a transaction dated Thursday, August 8th. The shares were sold at an average price of $96.39, for a total value of $192,780.00. Following the sale, the president now owns 98,980 shares in the company, valued at $9,540,682.20. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 1.50% of the company's stock.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.